Salani, R., Mirza, M. R., Lin, Z., Nishio, S., Oaknin, A., Kurtz, J. E., Valabrega, G., Cáceres, V., Harter, P., Gilbert, L., Sadozye, A., Barros, L. A. D. R., Gorp, T. V., Boere, I. A., Marth, C., Duska, L. R., Monk, B. J., Li, X. T., Tekin, C., Lindemann, K. (2025). TroFuse-020/GOG-3101/ENGOT-cx20: A phase 3, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy vs treatment of physician’s choice as second-line treatment for recurrent or metastatic cervical cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps5618